BidaskClub cut shares of Akcea Therapeutics (NASDAQ:AKCA) from a hold rating to a sell rating in a research report released on Saturday, January 6th.
AKCA has been the topic of several other reports. Zacks Investment Research cut shares of Akcea Therapeutics from a hold rating to a sell rating in a research note on Tuesday, October 10th. Cowen reissued a buy rating on shares of Akcea Therapeutics in a research note on Tuesday, October 31st. Finally, Stifel Nicolaus reissued a buy rating and set a $20.00 target price (up previously from $19.00) on shares of Akcea Therapeutics in a research note on Tuesday, November 7th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of Buy and a consensus target price of $22.75.
Akcea Therapeutics (NASDAQ AKCA) traded down $1.93 on Friday, reaching $21.65. 344,082 shares of the company were exchanged, compared to its average volume of 303,913. The firm has a market cap of $1,480.00 and a price-to-earnings ratio of -5.49. Akcea Therapeutics has a 1-year low of $8.10 and a 1-year high of $31.23.
Akcea Therapeutics (NASDAQ:AKCA) last posted its quarterly earnings results on Monday, November 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.03. sell-side analysts anticipate that Akcea Therapeutics will post -2.46 earnings per share for the current year.
Hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new stake in Akcea Therapeutics in the third quarter valued at approximately $111,000. Strs Ohio acquired a new stake in shares of Akcea Therapeutics in the third quarter worth $118,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Akcea Therapeutics in the third quarter worth $180,000. SG Americas Securities LLC acquired a new stake in shares of Akcea Therapeutics in the fourth quarter worth $121,000. Finally, Nationwide Fund Advisors acquired a new stake in shares of Akcea Therapeutics in the third quarter worth $209,000. Institutional investors and hedge funds own 26.06% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/01/31/bidaskclub-lowers-akcea-therapeutics-akca-to-sell.html.
Akcea Therapeutics Company Profile
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.